Plant Advanced Technologies SA (ALPAT.PA)
EUR 10.5
(-0.04%)
EUR 10.5
(-0.04%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.76 Million EUR | 199.1% |
| 2022 | -2.79 Million EUR | -1000.0% |
| 2021 | 310 Thousand EUR | 1247.83% |
| 2020 | 23 Thousand EUR | -90.87% |
| 2019 | 251.98 Thousand EUR | 47104.53% |
| 2018 | 533.81 EUR | -74.5% |
| 2017 | 2093.21 EUR | -18.89% |
| 2016 | 2580.85 EUR | 14.55% |
| 2015 | 2253.06 EUR | 30.3% |
| 2014 | 1729.09 EUR | -99.91% |
| 2013 | 2.03 Million EUR | 33.82% |
| 2012 | 1.51 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 FY | 2.76 Million EUR | 199.1% |
| 2023 Q2 | - EUR | 0.0% |
| 2022 Q4 | -2.94 Million EUR | 0.0% |
| 2022 FY | -2.79 Million EUR | -1000.0% |
| 2022 Q2 | 158 Thousand EUR | 0.0% |
| 2021 Q4 | 182 Thousand EUR | 0.0% |
| 2021 FY | 310 Thousand EUR | 1247.83% |
| 2021 Q2 | 281 Thousand EUR | 0.0% |
| 2020 Q4 | 44.75 Thousand EUR | 0.0% |
| 2020 FY | 23 Thousand EUR | -90.87% |
| 2020 Q2 | 39.83 Thousand EUR | 0.0% |
| 2019 FY | 251.98 Thousand EUR | 47104.53% |
| 2019 Q4 | 230.81 Thousand EUR | 0.0% |
| 2019 Q2 | 21.16 Thousand EUR | 0.0% |
| 2018 Q2 | 1017.75 EUR | 0.0% |
| 2018 Q4 | 483.94 EUR | 0.0% |
| 2018 FY | 533.81 EUR | -74.5% |
| 2017 Q4 | 1110.38 EUR | 0.0% |
| 2017 FY | 2093.21 EUR | -18.89% |
| 2017 Q2 | 982.83 EUR | 0.0% |
| 2016 Q2 | 1368.28 EUR | 0.0% |
| 2016 FY | 2580.85 EUR | 14.55% |
| 2016 Q4 | 1212.57 EUR | 0.0% |
| 2015 FY | 2253.06 EUR | 30.3% |
| 2015 Q4 | 1385.90 EUR | 0.0% |
| 2015 Q2 | 867.16 EUR | 0.0% |
| 2014 FY | 1729.09 EUR | -99.91% |
| 2014 Q2 | 809.16 EUR | 0.0% |
| 2014 Q4 | 919.93 EUR | 0.0% |
| 2013 Q1 | 86.6 Thousand EUR | 0.0% |
| 2013 Q3 | 86.6 Thousand EUR | 10815.54% |
| 2013 Q4 | 711.64 EUR | -99.18% |
| 2013 FY | 2.03 Million EUR | 33.82% |
| 2013 Q2 | 793.39 EUR | -99.08% |
| 2012 Q2 | 45.74 Thousand EUR | 0.0% |
| 2012 Q3 | 45.74 Thousand EUR | 0.0% |
| 2012 Q4 | 86.6 Thousand EUR | 89.33% |
| 2012 FY | 1.51 Million EUR | 0.0% |
| 2012 Q1 | 45.74 Thousand EUR | 0.0% |
| 2011 Q4 | 45.74 Thousand EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | 33.808% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 97.829% |
| Adocia SA | 15.62 Million EUR | 82.309% |
| Aelis Farma SA | 18.81 Million EUR | 85.308% |
| Biophytis S.A. | 14.33 Million EUR | 80.71% |
| Advicenne S.A. | 8.21 Million EUR | 66.344% |
| genOway Société anonyme | 16.73 Million EUR | 83.482% |
| IntegraGen SA | 5.35 Million EUR | 48.345% |
| Medesis Pharma S.A. | 1.56 Million EUR | -76.716% |
| Neovacs S.A. | 10.34 Million EUR | 73.27% |
| NFL Biosciences SA | 4.37 Million EUR | 36.794% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -60.938% |
| Sensorion SA | 27.05 Million EUR | 89.78% |
| Theranexus Société Anonyme | 3 Million EUR | 7.991% |
| TME Pharma N.V. | 5.49 Million EUR | 49.703% |
| Valbiotis SA | 9.86 Million EUR | 71.984% |
| TheraVet SA | 1.64 Million EUR | -68.146% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | 86.393% |
| DBV Technologies S.A. | 89.4 Million EUR | 96.908% |
| Genfit S.A. | 54.8 Million EUR | 94.955% |
| GeNeuro SA | 14.35 Million EUR | 80.743% |
| Innate Pharma S.A. | 64.57 Million EUR | 95.718% |
| Inventiva S.A. | 120.18 Million EUR | 97.7% |
| MaaT Pharma SA | 21.59 Million EUR | 87.199% |
| MedinCell S.A. | 32.92 Million EUR | 91.602% |
| Nanobiotix S.A. | 58.92 Million EUR | 95.308% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | 88.279% |
| Poxel S.A. | 28.76 Million EUR | 90.388% |
| GenSight Biologics S.A. | 32.66 Million EUR | 91.534% |
| Transgene SA | 31.23 Million EUR | 91.147% |
| Valneva SE | 134.92 Million EUR | 97.951% |